Veeva Systems (VEEV) Stock
Cloud software platform for life sciences companies. Here's the price, business snapshot, and what's worth knowing about Veeva Systems in August 2026.
Veeva Systems (VEEV) is a cloud‑software company focused on the life sciences industry, providing CRM, clinical, regulatory, quality and data platforms designed for pharmaceutical, biotech and medical‑device firms. It operates a subscription‑based model with high recurring revenue, which has supported steady margins and cash generation as the sector digitises. Key growth drivers include continued R&D outsourcing, regulatory complexity that favours specialised vendors, international expansion and cross‑selling of new modules to existing customers. Investors should note Veeva’s exposure to the healthcare sector and customer concentration in large pharma, which can amplify cyclicality. The shares currently reflect a premium for software‑like margins and growth; valuation and future revenue growth are important to watch. This is general information, not personal financial advice — returns can be volatile and past performance is not a guarantee. Consider whether the company’s sector concentration and valuation fit your risk tolerance and investment horizon.
Why It’s Moving
Veeva gains attention as earnings loom and a major pharma CRM win reinforces its growth story.
- Shares are moving as investors position ahead of Veeva’s August 26 earnings release, with the setup pointing to another check on execution and guidance momentum.
- Recent coverage has leaned on stronger-than-expected quarterly results and an upbeat analyst backdrop, reinforcing confidence that the company’s subscription-driven model is still delivering growth.
- Sentiment also improved after Eli Lilly committed to deploy Veeva Vault CRM globally, a win that signals continued traction with large pharma customers and supports the long-term platform story.
Veeva gains attention as earnings loom and a major pharma CRM win reinforces its growth story.
- Shares are moving as investors position ahead of Veeva’s August 26 earnings release, with the setup pointing to another check on execution and guidance momentum.
- Recent coverage has leaned on stronger-than-expected quarterly results and an upbeat analyst backdrop, reinforcing confidence that the company’s subscription-driven model is still delivering growth.
- Sentiment also improved after Eli Lilly committed to deploy Veeva Vault CRM globally, a win that signals continued traction with large pharma customers and supports the long-term platform story.
Sixth Month Growth Performance
When is the next earnings date for VEEVA SYSTEMS INC (VEEV)?
VEEV’s next earnings report is expected on August 26, 2026. It will cover fiscal Q2 2027, based on the company’s reporting cadence and the latest earnings schedule. For an investor briefing, that makes late August the key date to watch for the quarterly update.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Veeva's stock with a target price of $253.88, indicating potential growth.
Financial Health
Veeva Systems is showing strong profits and cash flow, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Recurring revenue model
Subscription contracts create predictable revenue and strong margins, though future growth depends on new customer wins and cross‑selling to existing clients.
Global pharma footprint
Veeva benefits from long relationships with major pharmaceutical companies and international expansion, but customer concentration can increase sector sensitivity.
Product innovation focus
Ongoing investment in specialised modules and data services supports cross‑sell opportunities, though competition and regulatory changes can affect adoption rates.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
